ECSP10010599A - Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk) - Google Patents

Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)

Info

Publication number
ECSP10010599A
ECSP10010599A EC2010010599A ECSP10010599A ECSP10010599A EC SP10010599 A ECSP10010599 A EC SP10010599A EC 2010010599 A EC2010010599 A EC 2010010599A EC SP10010599 A ECSP10010599 A EC SP10010599A EC SP10010599 A ECSP10010599 A EC SP10010599A
Authority
EC
Ecuador
Prior art keywords
tienopiridon
ampk
derivatives
protein kinase
activated protein
Prior art date
Application number
EC2010010599A
Other languages
English (en)
Inventor
Christine Charon
Daniel Cravo
Sophie Hallakou-Bozec
Franck Lepifre
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010599A publication Critical patent/ECSP10010599A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula (I) en donde R1, R2 y R3 son como se definen en la reivindicacion 1, incluyendo sus composiciones farmaceuticas y su uso en el tratamiento y/o la prevencion de enfermedades y trastornos modulados por agonistas de AMP. La invencion tambien se refiere a intermediarios y a un metodo de preparacion de compuestos de la formula (I).
EC2010010599A 2008-04-11 2010-11-09 Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk) ECSP10010599A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290364 2008-04-11

Publications (1)

Publication Number Publication Date
ECSP10010599A true ECSP10010599A (es) 2010-12-30

Family

ID=40671017

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010599A ECSP10010599A (es) 2008-04-11 2010-11-09 Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)

Country Status (26)

Country Link
US (1) US8563729B2 (es)
EP (1) EP2262500B1 (es)
JP (1) JP5592348B2 (es)
KR (1) KR101630466B1 (es)
CN (1) CN101998853B (es)
AU (1) AU2009235784B2 (es)
BR (1) BRPI0910439B8 (es)
CA (1) CA2721025C (es)
CO (1) CO6300954A2 (es)
DK (1) DK2262500T3 (es)
EA (1) EA017756B1 (es)
EC (1) ECSP10010599A (es)
ES (1) ES2584278T3 (es)
HK (1) HK1155955A1 (es)
HR (1) HRP20160907T1 (es)
HU (1) HUE027857T2 (es)
IL (1) IL208067A (es)
MX (1) MX2010011047A (es)
MY (1) MY155836A (es)
NZ (1) NZ589136A (es)
PL (1) PL2262500T3 (es)
PT (1) PT2262500T (es)
SI (1) SI2262500T1 (es)
UA (1) UA103321C2 (es)
WO (1) WO2009124636A1 (es)
ZA (1) ZA201008050B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2388485T3 (es) * 2008-05-05 2012-10-15 Merck Patent Gmbh Derivados de tienopiridona como activadores de proteína quinasa activada por AMP (AMPK)
JP5559894B2 (ja) * 2009-12-29 2014-07-23 ポクセル Ａｍｐｋのチエノ［２，３−ｂ］ピリジンジオンアクチベーターおよびその治療的使用
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130085169A1 (en) 2010-04-02 2013-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2611801B1 (de) * 2010-09-01 2016-05-04 Bayer Intellectual Property GmbH Herbizid wirksame ketosultame und diketopyridine
CA2830706A1 (en) * 2011-03-07 2012-09-13 Glaxosmithkline Llc Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) * 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
US9827222B2 (en) * 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
CN105037322A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环和烷氧苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN105001194A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一种含氨基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
MA42456B1 (fr) * 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
CN108463218A (zh) 2015-09-30 2018-08-28 药物分子研究所 减弱寄生虫毒性的方法
EP3478297A1 (en) 2016-06-30 2019-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
BR112021009270A2 (pt) * 2018-11-16 2021-08-10 Poxel sal de potássio mono-hidratado de um derivado de tienopiridona e seu processo de preparação
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
JP7427109B2 (ja) * 2020-03-26 2024-02-02 ポクセル 副腎白質ジストロフィー又は副腎脊髄ニューロパチーの処置におけるチエノピリドン誘導体の使用
US20230120204A1 (en) 2020-04-02 2023-04-20 Poxel Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd)
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626418B2 (en) 1989-05-16 1992-07-30 Merrell Pharmaceuticals Inc. Excitatory amino acid antagonists
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
US8273744B2 (en) 2008-02-04 2012-09-25 Mercury Therapeutics, Inc. AMPK modulators

Also Published As

Publication number Publication date
US20110034505A1 (en) 2011-02-10
AU2009235784A1 (en) 2009-10-15
HK1155955A1 (en) 2012-06-01
BRPI0910439A2 (pt) 2015-09-29
CN101998853A (zh) 2011-03-30
PT2262500T (pt) 2016-08-16
KR20100137563A (ko) 2010-12-30
SI2262500T1 (sl) 2016-09-30
ES2584278T3 (es) 2016-09-26
ZA201008050B (en) 2011-07-27
BRPI0910439B8 (pt) 2021-05-25
NZ589136A (en) 2012-06-29
CO6300954A2 (es) 2011-07-21
CA2721025A1 (en) 2009-10-15
WO2009124636A1 (en) 2009-10-15
BRPI0910439B1 (pt) 2020-10-20
IL208067A0 (en) 2010-12-30
EP2262500A1 (en) 2010-12-22
US8563729B2 (en) 2013-10-22
MY155836A (en) 2015-12-15
AU2009235784B2 (en) 2013-09-19
CA2721025C (en) 2016-07-26
JP2011516510A (ja) 2011-05-26
DK2262500T3 (en) 2016-08-15
MX2010011047A (es) 2010-10-26
PL2262500T3 (pl) 2016-09-30
EP2262500B1 (en) 2016-04-27
HRP20160907T1 (hr) 2016-09-23
EA201001585A1 (ru) 2011-06-30
EA017756B1 (ru) 2013-02-28
IL208067A (en) 2015-05-31
HUE027857T2 (en) 2016-11-28
JP5592348B2 (ja) 2014-09-17
UA103321C2 (ru) 2013-10-10
CN101998853B (zh) 2015-02-11
KR101630466B1 (ko) 2016-06-14

Similar Documents

Publication Publication Date Title
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
CO6331304A2 (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
CR11359A (es) Derivados de pirrolo (2,3-d) pirimidina como inhibidores de proteinas quinasa b
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
UY30835A1 (es) 8-alquinilxantinas y derivados
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
CR11814A (es) Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
ECSP10010642A (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes
ECSP077993A (es) Intermedios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina cinasa y metodos relacionados de sintesis